The Cooper Cos.
Pleasanton, California headquartered The Cooper Cos. Inc.'s stock finished Monday's session 4.03% lower at $170.13. A total volume of 635,795 shares was traded, which was above their three months average volume of 587,050 shares. The Company's shares have advanced 26.83% on an YTD basis. The stock is trading above its 200-day moving average by 2.33%. Furthermore, shares of Cooper Cos., which operates as a medical device company worldwide, have a Relative Strength Index (RSI) of 33.86.
On November 06th, 2016, Cooper Cos announced that CooperSurgical has acquired Wallace, the in-vitro fertilization segment of Smiths Medical, a division of Smiths Group PLC, for a purchase price of approximately $168 million subject to customary closing adjustments. Wallace reported sales of approximately $29 million in the last twelve months. Excluding non-recurring items and deal-related amortization, the transaction is expected to be approximately $0.10 accretive to earnings per share in fiscal 2017. The free research report on COO is available at:
On Monday, shares in California headquartered Glaukos Corp. ended the session at $33.78, down 0.68%. The stock recorded a trading volume of 1.28 million shares, which was higher than its three months average volume of 528,620 shares. The Company's shares have gained 7.68% in the previous three months and 36.82% since the start of this year. The stock is trading 26.54% above its 200-day moving average. Moreover, shares of Glaukos, which develops and commercializes products and procedures designed for the treatment of glaucoma, have an RSI of 45.34.
On October 27th, 2016, research firm Wells Fargo initiated an 'Outperform' rating on the Company's stock.
On November 10th, 2016, Glaukos reported a 56% net sales growth to $29.6 million in Q3 2016 compared to $19.0 million in Q3 2015. The company reported net income of $1.2 million, or $0.03 per diluted share, in Q3 2016 compared to a net loss of $2.1 million, or a loss of $0.07 per diluted share, in Q3 2015. The company raised 2016 net sales guidance to a range of $109 million to $111 million from the prior guidance range of $105 million to $107 million. The complimentary report on GKOS can be downloaded at:
Massachusetts headquartered Insulet Corp.'s stock ended yesterday's session 2.34% lower at $34.69. A total volume of 861,941 shares was traded, which was above their three months average volume of 540,060 shares. The Company's shares are trading 0.28% above their 200-day moving average. Additionally, shares of Insulet, which develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the US, have an RSI of 40.10.
On November 03rd, 2016, Insulet reported that Q3 2016 revenue increased 33% to $94.9 million compared to revenue from continuing operations of $71.4 million in Q3 2015. Operating income for the reported quarter was $2.4 million compared to an operating loss of $14.8 million in Q3 2015. The company's net loss from continuing operations for Q3 2016 was $3.0 million, or $0.05 per share, compared to a net loss from continuing operations of $18.0 million, or $0.32 per share, in Q3 2015. Visit us today and download our complete research report on PODD for free at:
At the close on Monday, shares in New Jersey headquartered CR Bard Inc. recorded a trading volume of 858,728 shares, which was above their three months average volume of 470,800 shares. The stock finished 4.44% lower at $203.77. The Company's shares have gained 8.08% since the start of this year. The stock is trading below its 200-day moving average by 4.93%. Furthermore, shares of CR Bard, which together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide, have an RSI of 32.16.
On October 25th, 2016, CR Bard reported net sales of $941.9 million for Q3 2016, an increase of 9% over Q3 2015. For Q3 2016, net sales in the U.S. were $646.0 million, an increase of 7% over Q3 2015. For the reported quarter, net income was $96.4 million and diluted earnings per share were $1.27, an increase of 212% and 209% respectively, as compared to Q3 2015 results. Get free access to your technical report on BCR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA